Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292326 | 0.78 | ALDH1A1 (0.34) | KDM4EL3MBTL1TDP1MEN1MAPT | |
| SCHEMBL1723475 | 0.75 | KCNH2 (0.42) | MAOBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2285150 | 0.74 | ALDH1A1 (0.34) | KDM4EL3MBTL1TDP1MAPTKMT2A | |
| SCHEMBL2293987 | 0.72 | ALDH1A1 (0.34) | L3MBTL1TDP1MEN1MAPTKMT2A | |
| SCHEMBL3411112 | 0.72 | PTGS2 (0.46) | PTGS2KDM4EL3MBTL1MAPTHSD17B10 | |
| SCHEMBL1711837 | 0.71 | PTGS2 (0.55) | PTGS2 | |
| SCHEMBL7494802 | 0.71 | NLRP3 (0.42) | KDM4EL3MBTL1TDP1MEN1MAPT | |
| SCHEMBL31618210 | 0.70 | HPGD (0.49) | KDM4EL3MBTL1TDP1MEN1MAPT | |
| SCHEMBL23485370 | 0.70 | SMN1; SMN2 (0.46) | MAOBKDM4EL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1867904 | 0.69 | NLRP3 (0.54) | KDM4EL3MBTL1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | PTGS2 4023/4885MAOB 2979/4885KDM4E 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.